meant was that the doctor should have the right to identify it if he desires to do so. That is only my opinion.

Senator NELSON. I have a couple more questions and we can move along.

(At this point in the hearing a short recess was taken.)

Senator NELSON. We will resume the hearings.

Dr. Slesser, on page 11 of your statement, you say,

> The inability of the FDA to assure even the competence of all drug firms, let alone the clinical quality of their products, is too long-standing to brush aside and the possibility of that situation soon or ever changing is extremely remote.

I think you also recited some statistics showing that they made less inspections recently. Was that less inspections this year than last?

Dr. SLESSER. Yes, sir.

Senator NELSON. Would your company support expanded appropriations for FDA so that the agency could do a better job of inspecting?

Dr. SLESSER. Yes, Senator. We certainly have concurred as a member of PMA in the past history of the PMA to do everything they could to encourage maximizing the budget for the Food and Drug Administration so that—so as to increase its staff, including inspectors.

Senator NELSON. Has your company ever appeared before the Appropriations or other committees in behalf of more staff for the FDA?

Dr. SLESSER. I do not know, Mr. Chairman.

Dr. SCHEELE. If I can answer. It has not been the practice of the Appropriations Subcommittees of the House or Senate to hear outside witnesses on such matters.

Mr. CUTLER. I am sure we have written letters, Senator Nelson, supporting appropriations for FDA.

Senator NELSON. I think it is a very serious matter that FDA does not have an adequate number of personnel in the field for better inspection and better enforcement to assure higher quality. I am sure from all the testimony we have had that certainly there is no member of the PMA who objects to that.

But in order to do something about it, I am wondering if the members of the PMA or the PMA itself is prepared to appear before Appropriation Committees and strongly endorse an expansion of FDA personnel for purposes of testing, inspection, and enforcement of higher standards in the manufacture of drug products. Can you answer that?

Mr. CUTLER. I believe, Senator, we have supported all of FDA's requests for appropriations, and we are on record and were on record in 1962 as supporting more frequent FDA inspections.

Senator NELSON. Good. I think that is very important. I am hopeful that we will be able to do something constructive about it in the near future, because I do not think it is any economy to economize on quality in this field.

One more question.

We had testimony yesterday from Dr. Helen Taussig. She testified in the same way as some other expert witnesses we have had respecting the labeling of bottles that go to patient from the pharmacist. This is not your responsibility, of course. She testified, as have some other witnesses, that she thought it was very important that the bottle that goes to the patient from the pharmacist have on the label